Hakutulokset - KRISTELEIT, REBECCA

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 Tekijä Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA Tekijä WOLFORD, JULIET E., BAI, JIARU, MOORE, KATHLEEN N., KRISTELEIT, REBECCA, MONK, BRADLEY J., TEWARI, KRISHNANSU S.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors Tekijä Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy Tekijä Milani, Andrea, Kristeleit, Rebecca, McCormack, Mary, Raja, Fharat, Luvero, Daniela, Widschwendter, Martin, MacDonald, Nicola, Mould, Tim, Olatain, Adeola, Hackshaw, Allan, Ledermann, Jonathan A

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts Tekijä Chung, Yuen-Li, Troy, Helen, Kristeleit, Rebecca, Aherne, Wynne, Jackson, L Elizabeth, Atadja, Peter, Griffiths, John R, Judson, Ian R, Workman, Paul, Leach, Martin O, Beloueche-Babari, Mounia

Hae kokoteksti Hae kokoteksti

An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials Tekijä Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies Tekijä Osborn, Gabriel, Stavraka, Chara, Adams, Rebecca, Sayasneh, Ahmad, Ghosh, Sharmistha, Montes, Ana, Lacy, Katie E, Kristeleit, Rebecca, Spicer, James, Josephs, Debra H, Arnold, James N, Karagiannis, Sophia N

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study Tekijä Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors Tekijä Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors Tekijä Brunetto, André T., Ang, Joo Ern, Lal, Rohit, Olmos, David, Molife, L. Rhoda, Kristeleit, Rebecca, Parker, Ann, Casamayor, Isabel, Olaleye, Muyibat, Mais, Anna, Hauns, Bernhard, Strobel, Vera, Hentsch, Bernd, de Bono, Johann S.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours Tekijä Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours Tekijä Bono, Petri, Massard, Christophe, Peltola, Katriina J, Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S, Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V J, Rodon, Jordi A

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Detection of circulating tumour cell clusters in human glioblastoma Tekijä Krol, Ilona, Castro-Giner, Francesc, Maurer, Martina, Gkountela, Sofia, Szczerba, Barbara Maria, Scherrer, Ramona, Coleman, Niamh, Carreira, Suzanne, Bachmann, Felix, Anderson, Stephanie, Engelhardt, Marc, Lane, Heidi, Evans, Thomas Ronald Jeffry, Plummer, Ruth, Kristeleit, Rebecca, Lopez, Juanita, Aceto, Nicola

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment Tekijä Rolfo, Christian, Isambert, Nicolas, Italiano, Antoine, Molife, L. Rhoda, Schellens, Jan H.M., Blay, Jean‐Yves, Decaens, Thomas, Kristeleit, Rebecca, Rosmorduc, Olivier, Demlova, Regina, Lee, Myung‐Ah, Ravaud, Alain, Kopeckova, Katerina, Learoyd, Maria, Bannister, Wendy, Locker, Gershon, de Vos‐Geelen, Judith

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... Tekijä Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

Hae kokoteksti Hae kokoteksti Hae kokoteksti

First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors Tekijä Sarker, Debashis, Ang, Joo Ern, Baird, Richard, Kristeleit, Rebecca, Shah, Krunal, Moreno, Victor, Clarke, Paul A., Raynaud, Florence I., Levy, Gallia, Ware, Joseph A, Mazina, Kathryn, Lin, Ray, Wu, Jenny, Fredrickson, Jill, Spoerke, Jill M, Lackner, Mark R, Yan, Yibing, Friedman, Lori S., Kaye, Stan B., Derynck, Mika K., Workman, Paul, de Bono, Johann S.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as mainten... Tekijä Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours Tekijä Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, Lopez, Juanita

Hae kokoteksti Hae kokoteksti Hae kokoteksti

A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer Tekijä Oza, Amit, Matulonis, Ursula, Alvarez Secord, Angeles, Roman, Lynda, Blagden, Sarah, Banerjee, Susana, Nemunaitis, John, McGuire, William, Ghamande, Sharad, Birrer, Michael, Fleming, Gini F, Jennifer Markham, Merry, Hirte, Hal, Provencher, Diane, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah, Schwartz, Benjamin, Braly, Patricia, Hall, Geoffrey, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

Hae kokoteksti Hae kokoteksti Hae kokoteksti

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre Tekijä Russell, Beth, Moss, Charlotte, Tsotra, Eirini, Gousis, Charalampos, Josephs, Debra, Enting, Deborah, Karampera, Christina, Khan, Muhammad, Roca, Jose, Sita-Lumsden, Ailsa, Owczarczyk, Kasia, Wylie, Harriet, Haire, Anna, Smith, Daniel, Zaki, Kamarul, Swampillai, Angela, Lei, Mary, Manik, Vishal, Michalarea, Vasiliki, Kristeleit, Rebecca, Mera, Anca, Sawyer, Elinor, Flanders, Lucy, De Francesco, Irene, Papa, Sophie, Ross, Paul, Spicer, James, Dann, Bill, Jogia, Vikash, Shaunak, Nisha, Kristeleit, Hartmut, Rigg, Anne, Montes, Ana, Van Hemelrijck, Mieke, Dolly, Saoirse

Hae kokoteksti Hae kokoteksti Hae kokoteksti